Evidence map›Paper›PMID 41736867›Full record

ArticleiScience2026

Neural network-assisted RNA velocity imputation for empowering transcript dynamics-based analyses.

Riku Egami, Momo Shirotori, Takashi Tamura, Sohei Oyama, Hideaki Mizuno

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Riku EgamiChugai Pharmaceutical Co., Ltd., Research Division, Yokohama, Kanagawa, Japan.
Momo ShirotoriChugai Pharmaceutical Co., Ltd., Digital Transformation Unit, Chuo-ku, Tokyo, Japan.
Takashi TamuraChugai Pharmaceutical Co., Ltd., Digital Transformation Unit, Chuo-ku, Tokyo, Japan.
Sohei OyamaChugai Pharmaceutical Co., Ltd., Research Division, Yokohama, Kanagawa, Japan.
Hideaki MizunoChugai Pharmaceutical Co., Ltd., Research Division, Yokohama, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Existing RNA velocity estimation tools often fail to calculate velocities for a substantial portion of genes due to technical limitations or model assumptions, thereby restricting downstream analyses that rely on velocity estimations. To tackle this problem, we propose NARVI (Neural Network-Assisted RNA Velocity Imputation), a deep learning framework that learns the relationship between the expression patterns and velocities of computable genes to accurately estimate velocities for otherwise incalculable genes. We evaluated the performance of NARVI across multiple single-cell transcriptome datasets and applied it to trajectory inference and marker gene analysis using the reconstituted velocities of dropped genes. This approach recovers velocities for thousands of genes that were previously impossible to estimate, thereby broadening the scope of downstream analyses and providing deeper insights into gene transcriptional dynamics.

Indexed as

biochemistrybiocomputational methodneural networks

Identifiers

PMID41736867
PMCPMC12927306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.